Loading…
Back To Schedule
Thursday, June 22 • 9:00am - 10:30am
#401: FDA Forum

Sign up or log in to save this to your schedule, view media, leave feedback and see who's attending!

Tweet Share
Feedback form is now closed.
Component Type: Forum
Level: Intermediate
CE: CME 1.50; IACET 1.50; RN 1.50

The FDA Forum will focus on inter-center collaboration between CDER, CDRH, CBER, and the Office of Combination Products. The recently established Oncology Center of Excellence will be highlighted as a new area of collaboration. FDA representatives will share how they collaborate to provide advice regarding products in development, review marketing applications, and help accelerate medical product approvals.

Learning Objectives

Discuss how the various centers in FDA collaborate to provide advice regarding products in development, review marketing applications, and help accelerate medical product approvals.

Chair

John Barlow Weiner, JD

Speaker

Panelist
Peter W. Marks, MD, PhD

Panelist
Angela C. Krueger

Panelist
Douglas C. Throckmorton, MD

Panelist
Tamy Kim, PharmD

Panelist
Paul Kluetz, MD


Speakers
avatar for Tamy Kim

Tamy Kim

Associate Director for Regulatory Affairs, OHOP and OCE (Acting), CDER, FDA
Tamy Kim is the Associate Director for Regulatory Affairs (ADRA) in the Office of Oncology and Hematology Products (OHOP) and Acting ADRA in the Oncology Center of Excellence (OCE) at the FDA. In OHOP, her responsibilities include developing policies related to review processes, including... Read More →
avatar for Paul Kluetz

Paul Kluetz

Deputy Director, Oncology Center of Excellence, OC, FDA, United States
Paul Kluetz is a medical oncologist and the Associate Director of Patient Outcomes in the Oncology Center of Excellence at the U.S. FDA. His interests include defining clinical benefit in oncology trials, the use of expedited programs such as accelerated approval, and opportunities... Read More →
AK

Angela Krueger

Acting Deputy Director, Office of Device Evaluation, CDRH, FDA
avatar for Peter Marks

Peter Marks

Director, Center for Biologics Evaluation and Research, FDA, United States
Peter Marks received his graduate degree in cell and molecular biology and his medical degree at New York University and completed Internal Medicine residency and Hematology/Medical Oncology training at Brigham and Women’s Hospital in Boston. He has worked in academic settings teaching... Read More →
avatar for Douglas Throckmorton

Douglas Throckmorton

Deputy Director, Regulatory Programs, OCD, CDER, FDA
As Deputy Director for Regulatory Programs, Dr. Throckmorton shares the responsibility for overseeing the regulation of research, development, manufacture and marketing of prescription, over-the-counter, and generic drugs in the United States.
avatar for John Weiner

John Weiner

Associate Director for Policy, Office of Combination Products, OCPP, OC, FDA, United States
John Barlow Weiner is the Associate Director for Policy in the Food and Drug Administration's Office of Combination Products, which is tasked with ensuring the sound and consistent regulation of combination products and also with the classification and assignment for regulation of... Read More →

Thursday June 22, 2017 9:00am - 10:30am CDT
S105 McCormick Place 2301 South Martin Luther King Jr. Drive, Gate 4 Chicago, IL 60616
  12: DIAmond, Forum
  • format json
  • Featured Topics Public Policy,Devices-Combination Products,StudentProgramming
  • Credit Type CME, IACET, RN
  • Tags Forum